Status:
COMPLETED
Valsartan and Amlodipine in Blood Pressure Management: Fixed-Dose vs. Free Drug Therapy
Lead Sponsor:
Shiraz University of Medical Sciences
Conditions:
Hypertension
Eligibility:
All Genders
35-70 years
Phase:
PHASE4
Brief Summary
Patients aged 35 to 70 years with newly diagnosed stage 1 or 2 hypertension ( HTN) was randomized to receive either Valsartan 80 mg/Amlodipine 5 mg fix dose combination (FDC) or a free equivalent comb...
Detailed Description
Patients were eligible for enrollment if they were between 35 and 70 years old and diagnosed with stage 1 or 2 hypertension at the time of enrollment, according to the 2017 ACC/AHA Guidelines (systoli...
Eligibility Criteria
Inclusion
- Patients diagnosed with stage 1 or 2 hypertension at the time of enrollment, according to the 2017 ACC/AHA Guidelines (systolic blood pressure \> 130 mmHg and/or diastolic blood pressure \> 80 mmHg), and required the initiation of antihypertensive medications
Exclusion
- Patients previously been on antihypertensive drugs
- Patients had secondary high blood pressure
- Patients had severe high blood pressure (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 110 mmHg)
- Patients had ischemic heart disease in the past
- Patients were unable to receive any part of the treatment
- Patients who refuse to take part in study
Key Trial Info
Start Date :
December 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
114 Patients enrolled
Trial Details
Trial ID
NCT06487949
Start Date
December 1 2022
End Date
December 1 2023
Last Update
July 5 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shiraz University of Medical Sciences
Shiraz, Fars, Iran, 713481433